| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2017-10-29 03:19:51 UTC |
|---|
| Update Date | 2019-07-23 14:38:48 UTC |
|---|
| HMDB ID | HMDB0240205 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | Bosutinib |
|---|
| Description | Bosutinib, also known as SKI 606, belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system. In humans, bosutinib is involved in the bosutinib inhibition of bcr-abl pathway. Bosutinib is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review a significant number of articles have been published on Bosutinib. |
|---|
| Structure | COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31) |
|---|
| Synonyms | | Value | Source |
|---|
| 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile | ChEBI | | SKI 606 | ChEBI | | SKI-606 | ChEBI | | Bosulif | HMDB |
|
|---|
| Chemical Formula | C26H29Cl2N5O3 |
|---|
| Average Molecular Weight | 530.446 |
|---|
| Monoisotopic Molecular Weight | 529.164745233 |
|---|
| IUPAC Name | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile |
|---|
| Traditional Name | bosutinib |
|---|
| CAS Registry Number | 380843-75-4 |
|---|
| SMILES | COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl |
|---|
| InChI Identifier | InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31) |
|---|
| InChI Key | UBPYILGKFZZVDX-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Quinolines and derivatives |
|---|
| Sub Class | Aminoquinolines and derivatives |
|---|
| Direct Parent | 4-aminoquinolines |
|---|
| Alternative Parents | |
|---|
| Substituents | - 4-aminoquinoline
- Methoxyaniline
- Aminophenyl ether
- Anisole
- 1,3-dichlorobenzene
- Phenol ether
- Aniline or substituted anilines
- Methoxybenzene
- Phenoxy compound
- Alkyl aryl ether
- N-alkylpiperazine
- N-methylpiperazine
- Aminopyridine
- Chlorobenzene
- Halobenzene
- Aryl chloride
- Benzenoid
- Aryl halide
- Pyridine
- Piperazine
- Monocyclic benzene moiety
- 1,4-diazinane
- Heteroaromatic compound
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Secondary amine
- Ether
- Carbonitrile
- Nitrile
- Organochloride
- Organonitrogen compound
- Organooxygen compound
- Organopnictogen compound
- Organic oxygen compound
- Amine
- Organohalogen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.68 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.1008 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.65 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1113.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 182.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 151.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 165.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 66.3 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 371.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 473.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 663.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 834.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 58.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 955.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 218.6 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 302.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 434.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 527.8 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 57.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Bosutinib,1TMS,isomer #1 | COC1=CC(N(C2=C(C#N)C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)[Si](C)(C)C)=C(Cl)C=C1Cl | 4083.6 | Semi standard non polar | 33892256 | | Bosutinib,1TMS,isomer #1 | COC1=CC(N(C2=C(C#N)C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)[Si](C)(C)C)=C(Cl)C=C1Cl | 3918.8 | Standard non polar | 33892256 | | Bosutinib,1TMS,isomer #1 | COC1=CC(N(C2=C(C#N)C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)[Si](C)(C)C)=C(Cl)C=C1Cl | 5712.6 | Standard polar | 33892256 | | Bosutinib,1TBDMS,isomer #1 | COC1=CC(N(C2=C(C#N)C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)[Si](C)(C)C(C)(C)C)=C(Cl)C=C1Cl | 4240.0 | Semi standard non polar | 33892256 | | Bosutinib,1TBDMS,isomer #1 | COC1=CC(N(C2=C(C#N)C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)[Si](C)(C)C(C)(C)C)=C(Cl)C=C1Cl | 4102.1 | Standard non polar | 33892256 | | Bosutinib,1TBDMS,isomer #1 | COC1=CC(N(C2=C(C#N)C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)[Si](C)(C)C(C)(C)C)=C(Cl)C=C1Cl | 5691.8 | Standard polar | 33892256 |
|
|---|
| MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Bosutinib , positive-QTOF | splash10-014i-0092000000-68183c460c3cf8e08c01 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Bosutinib , positive-QTOF | splash10-001l-1900080000-86f44693fc4098040447 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 10V, Positive-QTOF | splash10-001i-0200190000-83ef66b0c2abb8e9b17a | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 20V, Positive-QTOF | splash10-03dl-2904330000-ee3bd613842432d7081b | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 40V, Positive-QTOF | splash10-08ml-9504200000-cb1df01119e14f605420 | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 10V, Negative-QTOF | splash10-004i-0004090000-9c55d93dec61c52afac7 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 20V, Negative-QTOF | splash10-009j-3009240000-c553208a343087042f35 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 40V, Negative-QTOF | splash10-00di-1009000000-437a88d403cc82a326d3 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 10V, Positive-QTOF | splash10-001i-0000090000-1629a62e2e819fb0ea50 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 20V, Positive-QTOF | splash10-001i-0300590000-c9854475db68bc576d9c | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 40V, Positive-QTOF | splash10-0c00-3401920000-079555df03b2d8c82b35 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 10V, Negative-QTOF | splash10-004i-0000090000-6241b640c54394c3541c | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 20V, Negative-QTOF | splash10-004r-1108690000-356556ef25beb5e30365 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bosutinib 40V, Negative-QTOF | splash10-00di-1106940000-950a9f00a3b8c654573b | 2021-09-25 | Wishart Lab | View Spectrum |
|
|---|